Sintilimab plus anlotinib as second‐ or third‐line therapy in metastatic non‐small cell lung cancer with uncommon epidermal growth factor receptor mutations: A prospective, single‐arm, phase II trial

Abstract Background Patients with non‐small‐cell lung cancer (NSCLC) and uncommon EGFR alterations typically have worse treatment outcomes than patients with classically EGFR‐mutated NSCLC. This study aimed to investigate the efficacy and safety of PD‐1 blockade with sintilimab plus anti‐angiogenic...

Volledige beschrijving

Bibliografische gegevens

Hoofdauteurs:	Kaiyan Chen, Yanjun Xu, Zhiyu Huang, Xiaoqing Yu, Wei Hong, Hui Li, Xiaoling Xu, Hongyang Lu, Fajun Xie, Jun Chen, Youzu Xu, Yun Fan
Formaat:	Artigo
Taal:	Inglês
Gepubliceerd in:	Wiley 2023-10-01
Reeks:	Cancer Medicine
Onderwerpen:	anlotinib anti‐angiogenic non‐small cell lung cancer (NSCLC) PD‐1 sintilimab uncommon EGFR mutations
Online toegang:	https://doi.org/10.1002/cam4.6548
Tags:	Voeg label toe Geen labels, Wees de eerste die dit record labelt!